SURAMIN ATTENUATES DYSTROPHIN-DEFICIENT CARDIOMYOPATHY IN THE mdx MOUSE MODEL OF DUCHENNE MUSCULAR DYSTROPHY

dc.creatorMoreira, DD
dc.creatorPereira, JA
dc.creatorTaniguti, APT
dc.creatorMatsumura, CY
dc.creatorRamos, LAF
dc.creatorAreas, MA
dc.creatorNeto, HS
dc.creatorMarques, MJ
dc.date2013
dc.dateDEC
dc.date2014-07-30T20:07:09Z
dc.date2015-11-26T16:57:59Z
dc.date2014-07-30T20:07:09Z
dc.date2015-11-26T16:57:59Z
dc.date.accessioned2018-03-28T23:45:37Z
dc.date.available2018-03-28T23:45:37Z
dc.identifierMuscle & Nerve. Wiley-blackwell, v. 48, n. 6, n. 911, n. 919, 2013.
dc.identifier0148-639X
dc.identifier1097-4598
dc.identifierWOS:000327982300010
dc.identifier10.1002/mus.23858
dc.identifierhttp://www.repositorio.unicamp.br/jspui/handle/REPOSIP/74846
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/74846
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1277822
dc.descriptionFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
dc.descriptionConselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
dc.descriptionCoordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)
dc.descriptionIntroduction: The purpose of this study was to determine the effects of suramin, an antifibrotic agent, on cardiac function and remodeling in mdx mice. Methods: mdx mice (8 months old) received intraperitoneal injections of suramin twice a week for 3 months. Control mdx mice (8 months old) were injected with saline. Results: Suramin improved the electrocardiography profile with the main corrections seen in S- to R-wave ratio, PR interval, and Q amplitude, and a significant decrease in the cardiomyopathy index. Suramin decreased myocardial fibrosis, inflammation, and myonecrosis. Conclusions: These findings suggest that suramin may be a new adjunctive therapy to help improve cardiomyopathy in DMD. Muscle Nerve48: 911-919, 2013
dc.description48
dc.description6
dc.description911
dc.description919
dc.descriptionFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
dc.descriptionConselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
dc.descriptionCoordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)
dc.descriptionFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
dc.descriptionConselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
dc.descriptionCoordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)
dc.descriptionFAPESP [04/15526-9, 08/58491-1, 11/51697-6]
dc.descriptionCNPq [301306/2010-9, 302006/2009-5, 474708/06-3]
dc.descriptionFAPESP [140557/07-5, 2008/54775-5, 2012/03498-7]
dc.languageen
dc.publisherWiley-blackwell
dc.publisherHoboken
dc.publisherEUA
dc.relationMuscle & Nerve
dc.relationMuscle Nerve
dc.rightsfechado
dc.rightshttp://olabout.wiley.com/WileyCDA/Section/id-406071.html
dc.sourceWeb of Science
dc.subjectantifibrotic drugs
dc.subjectcardiomyopathy
dc.subjectDMD
dc.subjectmdx
dc.subjectsuramin
dc.subjectP2 Receptors
dc.subjectMyocardial Fibrosis
dc.subjectMice
dc.subjectTherapy
dc.subjectExpression
dc.subjectGrowth
dc.subjectCancer
dc.subjectChemotherapy
dc.subjectPerformance
dc.subjectImprovement
dc.titleSURAMIN ATTENUATES DYSTROPHIN-DEFICIENT CARDIOMYOPATHY IN THE mdx MOUSE MODEL OF DUCHENNE MUSCULAR DYSTROPHY
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución